Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype

Leukemia and Lymphoma

Volumn 25, Issue 5-6, 1997, Pages 545-554

  Pope, Belinda ^a   Brown, Ross ^a   Luo, Xiao Feng ^a   Gibson, John ^a   Joshua, Doug ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

CD38; Immunophenotype; Myeloma; Oncogene; Tumour suppressor gene

Indexed keywords

CD38 ANTIGEN; COMPLEMENTARY DNA; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL MEMBRANE PERMEABILITY; DNA PROBE; FLOW CYTOMETRY; HUMAN; IN SITU HYBRIDIZATION; MULTIPLE MYELOMA; ONCOGENE; ONCOGENE C FOS; ONCOGENE C MYC; ONCOGENE NEU; ONCOGENE RAS; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030802830     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709039043     Document Type: Article

References (33)

1. Vogelstein, B. and Kinger, K. W. (1993). The multistep nature of cancer, Trends Genet., 9, 138-141.
2. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M. and Bos, J. L. (1988). Genetic alterations during colorectal-tumor development. New Engl J. Med., 319, 525-532.
3. Leppert, M., Burt, R., Hughes, J. P., Samowitz, W., Nakamura, Y., Woodward, S., Gardner, E., Lalouel, J.-M. and White, R. (1990). Genetic analysis of an inherited predisposition to colon cancer in a family with a variable number of adenomatous polyps, New Engl J. Med., 322, 904-908.
4. Baker, S. J., Fearon, R., Nigro, M., Hamilton, S. R., Presinger, A. C., Jessup, J., van Tuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y. and White, R. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas, Science, 224, 217-221.
5. Bongiorno, P. F., Whyte, R. I., Lesser, E. J., Moore, J. H., Orringer, M. B. and Beer, D. G. (1994). Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas, J. Thorac Cardiovasc. Surg., 107, 590-595.
6. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. (1991). P53 mutations in human cancers, Science, 253, 49-53.
7. Iggo, R., Gatter, K., Bartek, J., Lane, D. and Harris, A. L. (1990). Increased expression of mutant forms of p53 oncogene in primary lung cancer, Lancet, 335, 675-679.
8. Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke-Pearson, D. I., Ingehart, J. D., Bast, R. C. and Berchuck, A. (1991). Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Research, 51, 2979-2984.
9. Kaltoff, H., Schmiegel, W., Roeder, C., Kasche, D., Schmidt, A., Lauer, G., Thiele, H. G., Honold, G., Pantel, K., Ritmuller, G., Scherer, E., Maurer, J., Maacke, H. and Deppert, W. (1993). P53 and K-ras alterations in pancreatic epithelial cell lesions, Oncogene, 8, 289-298.
10. Volkenandt, M., Schlegel, U., Nanus, D. M. and Albino, A. P. (1991). Mutational analysis of the human p53 gene in malignant melanoma, Pigment Cell. Res., 4, 35-40.
11. Kocialkowski, S., Pezzela, F., Morrison, H., Jones, M., Laha, S., Harris, A., Mason, D. Y. and Gatter, K. C. (1995). Mutations in the p53 gene are not limited to classic "hot spots" and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma, Br. J. Haematol., 89, 55-60.
12. Nobuyoshi, M., Kawano, M., Tanaka, H., Ishikawana, H., Tanabe, O., Iwato, K., Asaoku, H., Sakai, A. and Kauramoto, A. (1991). Increased expression of c-myc gene may be related to the aggressive transformation of human myeloma cells, Br. J. Haematol., 77, 523-528.
13. Paquette, R. L., Berensen, J., Lichtenstein, A., McCormick, F. and Koefler, H. P. (1990) Oncogenes in multiple myeloma: point mutations of N-ras, Cancer Res., 5, 1659-1663.
14. Palumbo, A. P., Boccadoro, M., Battaglio, S., Corradini, P., Tsichlis, P. N., Huebner, K. and Pileri, A. (1990). Human homologous of Moloney leukaemia virus integration-4 locus (MLVI-4) located 20 kilobases 3′ of the c-myc gene is rearranged in multiple myeloma, Cancer. Res., 50, 6478-6482.
15. Selvanayagam, P., Blick, M., Nami, F., van Tuinen, P. and Ledbetter, D. H. (1988). Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma, Blood, 71, 30-35.
16. Brown, R. D., Pope, B., Luo, X.-F., Gibson, J. and Joshua, D. E. (1994). The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk. Lymph., 16, 147-156.
17. Dao, D. D., Sawyer, J. R., Epstein, J., Hoover, R. G., Barlogie, B. and Tricot, G. (1994). Deletion of the retinoblastoma gene in multiple myeloma, Leukaemia, 8, 1280-1284.
18. Ahuja, H. G., Foti, A., Bar-Eli, M. and Cline, M. J. (1990). The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing, Blood, 75, 1684-1690.
19. Tanaka, K., Takechi, M., Asaoku, H., Dohy, H. and Kamada, N. (1992) A high frequency of N-RAS mutations in multiple myeloma, Int. J. Haematol., 56, 119-127.
20. Corradini, P., Ladetto, M., Voena, C., Inghirami, G. and Knowles, D. M. (1993). Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias, Blood, 81, 2708-2713.
21. Neri, A., Murphy, J. P., Cro, D., Ferroro, D., Tarella, C., Baldini, L. and Dalla-Favera, R. (1989). Ras oncogene mutations in multiple myeloma, J. Exp. Med., 170, 1715-1725.
22. Portier, M., Moles, J. P., Mazares, G. R., Jeanteu, P., Bataille, R., Klein, B. and Thillet, C. (1992). p53 and RAS gene mutations in multiple myeloma, Oncogene, 7, 2539-2543.
23. Corradini, P., Ingirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P., Gu, W., Nilsson, K., Knowles, D. M., Boccadoro, M., Pileri, A. and Dalla-Favero, R. (1994). Inactivation of tumour suppressor genes, p53 and Rb1 in plasma cell dyscrasias, Leukaemia, 8, 758-767.
24. Predholmme, C., Falcon, T., Zandecki, M., Vanrumbeke, M., Lai, J. L., Nataf, E., Loucheux-Lefebvre, M. H., Kerckaert, J. P. and Fenaux, P. (1992). Rare occurrence of p53 mutations in multiple myeloma, Br. J. Haematol., 81, 440-443.
25. Neri, A., Baldini, L., Treeca, D., Cro, L., Polli, E. and Maiolo, A. (1993) p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy, Blood, 81, 128-135.
26. Joshua, D. E., Snowdon, L., Gibson, J., Iland, H., Brown, R. D., Warburton, P., Kulakarni, A., Vincent, P., Young, G., Gatenby, P., Basten, A. and Kronenberg, H. (1991). Multiple myeloma Plateau phase revisited, Haematol. Rev., 5, 59-66.
27. Brown, R. D., Luo, X.-F., Gibson, J., Morley, A., Sykes, P., Brisco, M. and Joshua, D. E. (1995). Idiotypic oligonucleotide probes to detect myeloma cells by mRNA in situ hybridization, Br. J. Haematol., 90, 113-118.
28. Brown, R. D., Joshua, D. E., Nelson, M., Gibson, J., Dunn, J. and MacLennan, I. C. M. (1993). Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: Results from the MRC V. trial, Br. J. Haematol, 84, 238-241
29. Griepp, P. R., Witzig, T. and Gonchoroff, N. (1985). Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am. J. Hematol., 20, 289-292.
30. IFCC and ICSH. (1987). Approved recommendation on the theory of reference values, J. Clin. Chem. Clin. Biochem., 25, 645-656
31. Bergsagel, P. L., Chesi, M., Brents, L. A. and Kuehi, W. M. (1995). Translocations into IgH switch regions: the genetic hallmark of multiple myeloma, Blood, 86, Suppl 1, 59a.
32. Bergsagel, P. L., Chesi, M., Brents, L. A. and Kuehi, W. M. (1995). Dysregulation of c-myc in multiple myeloma: selective expression of one allele, Blood, 86 Suppl 1, 59a.
33. Imamura, J., Miyoshi, I. and Koeffler, H. P. (1994). p53 in hematologic malignancies, Blood, 84, 2412-2421.